- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371810
Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder (PROUD)
Pilot Randomized-controlled Phase-IIa Trial on the Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Frankfurt am Main, Germany
- Goethe University Hospital Frankfurt, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, and Department of Psychiatry, Psychosomatic Medicine and Psychotherapy
-
-
-
-
-
Nijmegen, Netherlands
- Radboud University Medical Centre, Karakter Child and Adolescent Psychiatry, and Department of Psychiatry
-
-
-
-
-
Barcelona, Spain
- Vall d'Hebron Research Institute, Group of Psychiatry, Mental Health and Addiction
-
-
-
-
-
London, United Kingdom
- King's College London, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
- Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise)
Exclusion Criteria:
- Intelligence Quotient (IQ) below 75
- Any severe (comorbid) psychiatric disorder with necessary additional psychopharmaco or daycare/ inpatient therapy beyond treatment as usual
- Severe medical/ neurological condition not allowing bright light therapy or exercise
- History of epilepsy
- Use of antipsychotics, antiepileptic or photosensitising medication
- Substance abuse/ dependency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bright light therapy
Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total. Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed. |
Mobile therapeutic light (10.000
LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419).
Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
Other Names:
|
Experimental: Physical exercise
Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total. Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed. |
During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually. Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity.
Other Names:
|
No Intervention: Treatment as usual
Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in clinician-rated depressive symptoms (observer-blinded assessment)
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Inventory of Depressive Symptomatology (clinician-rated)
|
baseline, end of intervention (10 weeks after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in clinician-rated depressive symptoms (observer-blinded assessment)
Time Frame: baseline, follow up (22 weeks after baseline)
|
Inventory of Depressive Symptomatology (clinician-rated)
|
baseline, follow up (22 weeks after baseline)
|
Change from baseline in clinician-rated ADHD symptoms
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
ADHD Rating Scales for adults and children
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in self-reported severity of depressive symptoms
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Beck Depression Inventory II
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in self-reported health status
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Health Questionnaire EQ-5D-3L
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in self-reported health related quality of life
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Short Form Health Questionnaire General Health Questionnaire
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in self-reported general health status
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
General Health Questionnaire General Health Questionnaire
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in self-reported emotional and behavioural problems in adolescents
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Youth self-report
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in self-reported emotional and behavioural problems in adults
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Adult self-report
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in circadian rhythm
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Munich Chronotype Questionnaire
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in cognitive emotion regulation
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Cognitive Emotion Regulation Questionnaire
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in neurocognitive functions: verbal memory
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Rey Auditory Verbal Learning Test
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in neurocognitive functions: Digit span
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Digit span
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in self-reported physical fitness
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
International Fitness Scale
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in general muscular fitness
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
handgrip strength test
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in muscular fitness
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
standing long jump test
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in aerobic fitness
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Chester step test
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in body mass index
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
body mass index measured by clinician
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in waist circumference
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
waist circumference measured by clinician
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in waist-to-hip ratio
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
waist-to-hip ratio measured by clinician
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in body fat percentage
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
based on skinfold thickness measurements using a skinfold caliper
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in heart rate
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
heart rate measured by clinician
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in blood pressure
Time Frame: baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
blood pressure measured by clinician
|
baseline, end of intervention (10 weeks after baseline), follow-up (22 weeks after baseline)
|
Change from baseline in number of steps
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
number of steps measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in movement acceleration
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
movement acceleration measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in sleep time
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
sleep time measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in context parameters
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
context measured with the mobile Health
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in mood regulation
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
mood regulation measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in reward reactivity
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
reward reactivity measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in stress reactivity
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
stress reactivity measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in inattention
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
inattention measured with the mobile Health app
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in melatonin concentration
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Saliva sample will be taken to measure melatonin concentration
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in cortisol concentration
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Saliva sample will be taken to measure cortisol concentration
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in leptin concentration
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Saliva sample will be taken to measure leptin concentration
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in ghrelin concentration
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Saliva sample will be taken to measure ghrelin concentration
|
baseline, end of intervention (10 weeks after baseline)
|
Change from baseline in neural activity associated with reward processing
Time Frame: baseline, end of intervention (10 weeks after baseline)
|
Striatal functional magnetic resonance imaging signal related to reward processing
|
baseline, end of intervention (10 weeks after baseline)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine M Freitag, Prof. Dr., Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Goethe University Frankfurt am Main
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Depression
- Depressive Disorder
- Obesity
- Disease
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
Other Study ID Numbers
- CoCA-PROUD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Bright light therapy
-
Sunnybrook Health Sciences CentreCompletedMajor Depressive Disorder | Seasonal Affective Disorder | NeuroimagingCanada
-
Hospital Authority, Hong KongUnknown
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingBladder Carcinoma | Kidney Carcinoma | Prostate Carcinoma | Genitourinary System NeoplasmUnited States
-
Chinese University of Hong KongRecruiting
-
Erasmus Medical CenterNot yet recruiting
-
VA Office of Research and DevelopmentRecruiting
-
Maimonides Medical CenterFoundation for Prader-Willi ResearchRecruitingBody Weight | Hyperphagia | Prader-Willi Syndrome | Mood | Behavior | Excessive Daytime SleepinessUnited States
-
University of OuluOulu University Hospital; University of Eastern Finland; ODL Terveys Oy; Valkee OyUnknownSeasonal Affective DisorderFinland
-
Universidade da CoruñaCompletedDementia | Mood | BehaviorSpain
-
Hospices Civils de LyonCompleted